Relationships of uPA and VEGF Expression in esophageal cancer and microvascular density with tumorous invasion and metastasis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3379-3383

  Jiang, Jian Tao ^a   Zhang, Lan Fang ^a   Zhou, Bin ^a   Zhang, Shun Qun ^b   Li, Shao Min ^a   Zhang, Wei ^a   Zhang, Jin ^a   Qiao, Zhe ^a   Kong, Ran Ran ^a   Ma, Yue Feng ^a   Chen, Sheng ^c  

^a The Third Hospital of Xinxiang Medical University   (China)

^b THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Esophageal cancer; Immunohistochemistry; uPA; VEGF

Indexed keywords

EID: 84873602253     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3379     Document Type: Article

References (21)

1. Bosari S, Lee AK, Delellis RA, et al (1992). Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol, 23, 755-61.
2. Cavallaro U, Tenan M, Castelli V, et al (2001). Response of bovine endothelial cells to FGF-2 and VEGF is dependenton their site of origin: Relevance to the regulation of angiogenesis. J Cell Biochem, 82, 619-33.
3. Conn EM, Botkjaer KA, Kupriyanova TA, et al (2009). Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion. Am J Pathol, 175, 1638-52.
4. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 146, 1029-39.
5. Huang HY, Jiang ZF, Li QX, et al (2010). Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator. Cancer Invest, 28, 689-97.
6. Iseki K, Tat Suata M, Uehara H, et al (1999). Inhibitor of angiogenesis as a mechanism for inhibitor by 1α-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymet hane in Wistar rat. Int Cancer, 81, 730-3.
7. Isogai C, Laug WE, Shimada H, et al (2001). Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res, 61, 5587-94.
8. Kang ZQ, Jiang B, Li P, Wang YJ (2003). Expression of urokinase-type plasminogen activator in non-small cell lung cancer. Academic J Second Military Medical University, 24, S4-5.
9. Katoh Y, Katoh M (2006). Comparative integromics on VEGF family members. Int J Oncol, 28, 1585-9.
10. Liu G, Zhang W, Jiang P, et al (2012). Role of nitric oxide and vascular endothelial growth factor in fluoride-induced goitrogenesis in rats. Environ Toxicol Pharmacol, 34, 209- 17.
11. Mazar AP (2008). Urokinase plasminogen activator receptor choreographs multiple ligand interaetions: implieations for tumor progression and therapy. Clin Cancer Res, 14, 5649-55.
12. Pengchong H, Tao H (2011). Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol, 32, 660-4.
13. Qin R, Sheng X, Wu JF, Wang DB (2005). Expression of urokinase-type plasminogen activator system and vascular endothelial growth factor in human gastric cancer and the relationship with tumor invasion and metastasis. World Chin J Digestol, 13, 706-10.
14. Reuning U, Magdolen V, Hapke S, Schmitt M (2003). Molecular and functional interdependence ofthe urokinase-type plasminogen activatorsystem with integrins. Biol Chem, 384, 1119-31.
15. Schmitt M, Harbeck N, Brunner N, et al (2011). Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diadn, 11, 617-34.
16. Schmitt M, Harbeck N, Thomssen C, et al (1997). Clinical impact of the plasminogen activation and target for therapy. Thromb Haemost, 78, 285-96.
17. Viacava P, GasperiM, Acerbi G, et al (2003). Microvasscular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. Endocrinol Invest, 26, 23-8.
18. Xiao JP, Zhang L, Qi Y, Gong P (2007). Expression and Significance of uPA and VEGF in Breast Carcinoma. Chin J General Surgery, 16, 93-6.
19. Yoshizawa K, Nozaki S, Kitahara H, et al (2011). Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors. Oncol Rep, 26, 1555-60.
20. Zhang QX, Magovern CJ, Mack CA, et al (1997). Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res, 67, 147-54.
21. Zhang Y, Han J, Yang X, et al (2011). Pigment epithelium-derived factor inhibits angiogenesis and growth of gastric carcinoma by down-regulation of VEGF. Oncol Rep, 26, 681-6.